Physician profile
Michael L Yu
NPI 1073727301
$10,243.03
in general payments reported to CMS, 2019-2025
76 companies · $2,676 in 2025
The $2,676 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $450 · 2021: $1,076 · 2022: $956 · 2023: $1,371 · 2024: $3,269 · 2025: $2,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,192 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,191.76 |
| Education | $124.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $870.18 | 2019-2025 | Ubrelvy |
| Ucb, INC. | $774.48 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Inspire Medical Systems, INC. | $622.10 | 2023-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $473.37 | 2019-2025 | |
| Biogen, INC. | $448.96 | 2019-2025 | Vumerity, Plegridy, Avonex |
| Emd Serono, INC. | $425.64 | 2020-2025 | Mavenclad |
| Ani Pharmaceuticals, INC. | $414.72 | 2024-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $407.48 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $343.42 | 2019-2025 | Ultomiris, Soliris, Strensiq |
| Lilly USA, LLC | $302.97 | 2019-2025 | Amyvid, Emgality, Kisunla |
| Lundbeck LLC | $297.48 | 2021-2025 | Vyepti, Rexulti |
| Eisai INC. | $286.39 | 2020-2025 | |
| Pfizer INC. | $247.62 | 2023-2025 | |
| Genentech USA, INC. | $244.28 | 2023-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Acadia Pharmaceuticals INC | $174.99 | 2019-2025 | Nuplazid |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.